Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer

Area of Science:

• Biochemistry
• Immunology
• Oncology

Background:

• Sialic acids, particularly increased sialoglycan density (hypersialylation), are observed in tumors.
• Tumor cells and microorganisms exploit sialoglycan-Siglec interactions for immune evasion.
• Siglec receptors function as inhibitory immune checkpoints, similar to PD-1 and CTLA-4.

Purpose of the Study:

• To summarize alterations in sialic acids within cancer.
• To elucidate the role of Siglec receptors in cancer immunity.
• To explore therapeutic strategies targeting Siglec receptors or sialoglycans for enhanced anti-cancer immunity.

Main Methods:

• Literature review of studies on sialic acids in cancer.
• Analysis of sialoglycan-Siglec interactions in tumor immune evasion.
• Review of current and potential immunotherapeutic approaches targeting these pathways.

Main Results:

• Hypersialylation is a common feature of tumors, facilitating immune evasion.
• Siglec-mediated immune suppression by cancer cells is a significant challenge in immunotherapy.
• Targeting Siglecs or sialoglycans presents a promising strategy for improving cancer treatment.

Conclusions:

• Understanding sialic acid modifications and Siglec receptor roles is crucial for cancer immunology.
• Targeting the sialoglycan-Siglec axis holds potential for novel cancer immunotherapies.
• Further research into these mechanisms could lead to more effective anti-cancer treatments.